Comparing two medications (dexamethasone and methylprednisolone high dose) for the treatment of pneumonia in patients with COVID-19
- Conditions
- COVID-19 (SARS-CoV-2 infection) related pneumoniaInfections and Infestations
- Registration Number
- ISRCTN33037282
- Lead Sponsor
- Clínica Medellín - Grupo Quirónsalud
- Brief Summary
2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34033648/ (added 14/03/2022)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 213
1. Over 18 years of age
2. Hospitalized with COVID-19 pneumonia confirmed by positive Real-Time Reverse Transcription Polymerase Chain Reaction for SARS-CoV2 (RT-PCR SARS-CoV-2) by Berlin protocol
3. Radiological confirmation of pneumonia
1. Contraindications associated with corticosteroids
2. Dissent for medical management
3. Death in the first 24 hours
4. Patient in palliative care or with a life expectancy of fewer than 6 months
5. If the patient required admission to the ICU and did not receive at least two doses of the corticosteroid
6. If the patient receives at least two doses of methylprednisolone but did not continue with prednisone, they were not included, but their outcome continued to be monitored
7. Patients who also received less than 2 days of dexamethasone treatment were withdrawn from study follow-up
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method